肝脏靶向药物对血糖和肝脏脂质的影响
本文综述了非酒精性脂肪性肝病(NAFLD)和脂肪性肝炎(NASH)在2型糖尿病患者中的高流行性,并总结了在研的肝脏靶向药物(包括核激素受体激动剂、FGF-19/21、肠促胰岛素、SGLT抑制剂等)对糖尿病高血糖和脂肪肝的代谢效应及其对外周代谢和胰岛素抵抗的影响。
要点
- 多种降糖药物正被测试用于NAFLD/NASH治疗。
- 肝脏靶向药物可能同时改善血糖和肝脏脂质。
- 需关注药物对外周代谢和胰岛素抵抗的影响。
核心结论
- 综述了肝脏靶向药物对糖尿病高血糖和脂肪肝疾病的代谢效应。
研究设计与样本
- 综述性文章,检索范围未明确报告。
主要发现
- 核激素受体激动剂、FGF-19/21、单/双/三肠促胰岛素、SGLT抑制剂等药物在研。
- 这些药物可能改善糖尿病高血糖和脂肪肝疾病。
- 药物还影响外周代谢和胰岛素抵抗。
临床怎么用
- 内分泌科医生应关注肝脏靶向药物在NAFLD/NASH合并2型糖尿病中的潜在应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium-glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance.
引用
- Gastaldelli A, Stefan N, Häring HU, et al. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia. 2021. PMID: 33877366. doi:10.1007/s00125-021-05442-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。